Other than that, it remains to be tested is its efficiency in avoiding the development of a severe pneumonia in patients with high levels of BiP in blood, but it is clear that 4-PBA is a strong candidate for the treatment of ARDS and that it seems like a viable option due to the fact that it is an approved drug. Here, HSPA5 is linked to susceptibility to pneumonia measurement.